In cases of ANGELIQ (drospirenone and estradiol) overdose, monitor serum concentrations of potassium and sodium since drospirenone has antimineralocorticoid properties.

Serious ill effects have not been reported following acute ingestion of large doses of progestin/estrogen-containing oral contraceptives by young children. Overdosage may cause nausea and withdrawal bleeding may occur in females.

Progestogens/estrogens should not be used in individuals with any of the following conditions:

1. Undiagnosed abnormal genital bleeding.
2. Known, suspected, or history of cancer of the breast.
3. Known or suspected estrogen-dependent neoplasia.
4. Active deep vein thrombosis, pulmonary embolism or history of these conditions.
5. Active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction).
6. Renal insufficiency.
7. Liver dysfunction or disease.
8. Adrenal insufficiency.
9. ANGELIQ (drospirenone and estradiol) should not be used in patients with known hypersensitivity to its ingredients.
10. Known or suspected pregnancy. There is no indication for ANGELIQ (drospirenone and estradiol) in pregnancy. There appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins from oral contraceptives inadvertently during early pregnancy. (See PRECAUTIONS).

Last reviewed on RxList: 1/16/2009
This monograph has been modified to include the generic and brand name in many instances.